Trastuzumab-induced cardiotoxicity: Clinical and prognostic implications of troponin I evaluation

Journal of Clinical Oncology

Volumn 28, Issue 25, 2010, Pages 3910-3916

  Cardinale, Daniela ^a   Colombo, Alessandro ^a   Torrisi, Rosalba ^a   Sandri, Maria T ^a   Civelli, Maurizio ^a   Salvatici, Michela ^a   Lamantia, Giuseppina ^a   Colombo, Nicola ^a   Cortinovis, Sarah ^a   Dessanai, Maria A ^a   Nolè, Franco ^a   Veglia, Fabrizio ^a   Cipolla, Carlo M ^a  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; ANTIARRHYTHMIC AGENT; ANTICOAGULANT AGENT; CAPECITABINE; CARVEDILOL; CYCLOPHOSPHAMIDE; DIURETIC AGENT; DOXORUBICIN; ENALAPRIL; EPIRUBICIN; METHOTREXATE; NAVELBINE; PACLITAXEL; TAXANE DERIVATIVE; TRASTUZUMAB; TROPONIN I; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ACUTE CORONARY SYNDROME; ADULT; ANTICOAGULANT THERAPY; ARTICLE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL ASSESSMENT; CONVALESCENCE; DRUG DOSE TITRATION; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HAZARD RATIO; HEART ARRHYTHMIA; HEART DEATH; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; IMMUNOASSAY; LUNG EDEMA; MAJOR CLINICAL STUDY; MAXIMUM TOLERATED DOSE; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; RISK FACTOR; TRASTUZUMAB INDUCED CARDIOTOXICITY; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; BREAST TUMOR; CHEMICALLY INDUCED DISORDER; DRUG INTERACTION; EVALUATION; HEART DISEASE; HEART LEFT VENTRICLE FUNCTION; METABOLISM; MIDDLE AGED; RETROSPECTIVE STUDY; RISK;

ADULT; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; DRUG INTERACTIONS; FEMALE; HEART DISEASES; HUMANS; MIDDLE AGED; PROGNOSIS; RETROSPECTIVE STUDIES; RISK; TREATMENT OUTCOME; TROPONIN I; VENTRICULAR DYSFUNCTION, LEFT;

EID: 77957567061     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2009.27.3615     Document Type: Article

References (34)

1. Gusterson BA, Gelber RD, Goldhirsch A, et al: Prognostic importance of c-erbB-2 expression in breast cancer: International (Ludwig) Breast Cancer Study Group. J Clin Oncol 10:1049-1056, 1992
2. Slamon DJ, Leyland-Jones B, Shak S, et al: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783-792, 2001 (Pubitemid 32222155)
3. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al: Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353:1659-1672, 2005 (Pubitemid 41464705)
4. Smith I, Procter M, Gelber RD, et al: 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: A randomized controlled trial. Lancet 369:29-36, 2007 (Pubitemid 46039831)
5. Telli ML, Hunt SA, Carlson RW, et al: Trastuzumab-related cardiotoxicity: Calling into question the concept of reversibility. J Clin Oncol 25:3525-3533, 2007 (Pubitemid 47310891)
6. Seidman A, Hudis C, Pierri MK, et al: Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol 20:1215-1221, 2002 (Pubitemid 34177427)
7. Yeh ET, Bickford CL: Cardiovascular complications of cancer therapy: Incidence, pathogenesis, diagnosis, and management. J Am Coll Cardiol 53:2231-2247, 2009
8. Guglin M, Hartlage G, Reynolds C, et al: Trastuzumab-induced cardiomyopthy: Not as benign as it looks? A retrospective study. J Card Fail 15:651-657, 2009
9. Ewer MS, Vooletich MT, Durand JB, et al: Reversibility of trastuzumab-related cardiotoxicity: New insights based on clinical course and response to medical treatment. J Clin Oncol 23:7820-7826, 2005 (Pubitemid 46657379)
10. Ewer MS, Lippman SM: Type II chemotherapy-related cardiac dysfunction: Time to recognize a new entity. J Clin Oncol 23:2900-2902, 2005 (Pubitemid 46224107)
11. Suter TM, Ewer MS: Trastuzumab-associated cardiotoxicity, in Ewer MS, Yeh ET (eds): Cancer and the Heart. Hamilton, British Columbia, Canada, Decker, 2006, pp 67-74
12. Guarneri V, Lenihan DJ, Valero V, et al: Long-term cardiac tolerability of trastuzumab in metastatic breast cancer: The M.D. Anderson Cancer Center experience. J Clin Oncol 24:4107-4115, 2006 (Pubitemid 46622286)
13. Rastogi P, Jeong J, Geyer CE, et al: Five year update of cardiac dysfunction on NSABP B-31, a randomized trial of sequential doxorubicin/ cyclophosphamide (AC)→paclitaxel (T) vs. AC→T with trastuzumab (H). J Clin Oncol 25:6s, 2007 (suppl; abstr LBA513)
14. Bird BR, Swain SM: Cardiac toxicity in breast cancer survivors: Review of potential cardiac problems. Clin Cancer Res 14:14-24, 2008 (Pubitemid 351377973)
15. Jones RL, Ewer MS: Cardiac and cardiovascular toxicity of nonanthracycline anticancer drugs. Expert Rev Anticancer Ther 6:1249-1269, 2006 (Pubitemid 44575578)
16. Cardinale D, Sandri MT, Martinoni A, et al: Left ventricular dysfunction predicted by early troponin I release after high-dose chemotherapy. J Am Coll Cardiol 36:517-522, 2000
17. Cardinale D, Sandri MT, Colombo A, et al: Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dosechemotherapy. Circulation 109:2749-2754, 2004 (Pubitemid 38737923)
18. Cardinale D, Colombo A, Sandri MT, et al: Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensinconverting enzyme inhibition. Circulation 114:2474-2481, 2006 (Pubitemid 44901520)
19. Suter TM, Procter M, van Veldhuisen DJ, et al: Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial. J Clin Oncol 25:3859-3865, 2007 (Pubitemid 47477261)
20. Lang RM, Bierig M, Devereux RB, et al: Recommendations for chamber quantification: A report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr 18:1440-1463, 2005 (Pubitemid 41821197)
21. Swedberg K, Cleland J, Dargie H, et al: Guidelines for the diagnosis and treatment of chronic heart failure: Executive summary (update 2005) - The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Eur Heart J 26:1115-1140, 2005
22. Libby P, Bonow RO, Mann DL, et al: The cancer patient and cardiovascular disease, in Braunwald E (ed): Heart Disease: A Textbook of Cardiovascular Medicine. Philadelphia, PA, Saunders Elsevier, 2008, pp 2105-2117
23. Guglin M, Cutro R, Mishkin JD: Trastuzumab-induced cardiomyopathy. J Card Fail 14:437-444, 2008 (Pubitemid 351749842)
24. Ewer SM, Ewer MS: Cardiotoxicity profile of trastuzumab. Drug Saf 31:459-467, 2008 (Pubitemid 351695459)
25. Perez EA: Cardiac issues related to trastuzumab. Breast 13:171-172, 2004
26. Perik PJ, de Korte MA, van Veldhuisen DJ, et al: Cardiotoxicity associated with the use of trastuzumab in breast cancer patients. Expert Rev Anticancer Ther 7:1763-1771, 2007 (Pubitemid 350303006)
27. Ewer MS, Perez EA, Baselga J, et al: Cardiac safety guidelines for the adjuvant use of trastuzumab in HER2-positive early breast cancer. Breast 16:S63, 2007 (suppl 1; abstr P176)
28. Mackey JR, Clemons M, Côté MA, et al: Cardiac management during adjuvant trastuzumab therapy: Recommendations of the Canadian Trastuzumab Working Group. Curr Oncol 15:24-35, 2008
29. Jones AL, Barlow M, Barrett-Lee PJ, et al: Management of cardiac health in trastuzumab-treated patients with breast cancer: Updated United Kingdom National Cancer Research Institute recommendations for monitoring. Br J Cancer 100:684-692, 2009
30. Keefe DL: Trastuzumab-associated cardiotoxicity. Cancer 95:1592-1600, 2002
31. Swain SM, Whaley FS, Ewer MS: Congestive heart failure in patients treated with doxorubicin: A retrospective analysis of three trials. Cancer 97:2869-2879, 2003 (Pubitemid 36605157)
32. Cardinale D, Sandri MT, Martinoni A, et al: Myocardial injury revealed by plasma troponin I in breast cancer treated with high-dose chemotherapy. Ann Oncol 13:710-715, 2002 (Pubitemid 34567376)
33. Cardinale D, Colombo A, Lamantia G, et al: Anthracycline-induced cardiomyopathy: Clinical relevance and response to pharmacologic therapy. J Am Coll Cardiol 55:213-220, 2010
34. Kloner RA, Jennings RB: Consequences of brief ischemia: Stunning, preconditioning, and their clinical implications - Part 2. Circulation 104:3158-3167, 2001 (Pubitemid 34014074)